EUVIMEDAtrasti EUVIMED
Open access

Characterization of SHCBP1 to prognosis and immunological landscape in pan-cancer: novel insights to biomarker and therapeutic targets

Fei Jiang, Yanlong Shi, Yue Wang, Chang Ge, Jun Zhu, Hanlu Fang, Yu Zhang, Yixiao Zhang, Haokun Jian, Tong Lei, Sheng Lan, Liyu Cao and 2 more

Aging · 2023

DOI: 10.18632/aging.204591 ↗

At a glance

Journal article in Aging, 2023. Written by Fei Jiang and 13 co-authors. Institution: Department of General Surgery, Fuyang Hospital of Anhui Medical University, Fuyang, Anhui, China. Major MEDLINE topics: Neoplasms. Cited 5 times so far (Crossref); 35 references. The full text is freely available in PubMed Central.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

BACKGROUND: Previous studies have revealed the significant roles of SHC SH2 domain-binding protein 1 (SHCBP1) in occurrence and progression of cancers, but there is no pan-cancer analysis of SHCBP1. METHODS: In this study, we explored the potential carcinogenic role of SHCBP1 across 33 tumors from the TCGA and GTEx databases. We investigated SHCBP1 expression, prognosis, genetic alterations, tumor mutational burden (TMB) score, microsatellite instability (MSI) and tumor microenvironment from TIMER2, GEPIA2, UALCAN and cBioPortal databases. Moreover, the cellular functions and potential mechanisms were evaluated by GO and KEGG analysis. Besides, the mRNA expression of SHCBP1 was examined using qRT-PCR assay in gastrointestinal cancers. RESULTS: SHCBP1 was significantly upregulated in various cancers, and apparent relationship existed between SHCBP1 and survival prognosis in patients. The TMB, MSI, and tumor microenvironment analysis indicated that SHCBP1 was closely related to immune checkpoints, immune targets, as well as CD4+ naive T cell, CD8+ T cell, and neutrophil. Moreover, the cellular functions of SHCBP1 were mainly in regulating cell cycle motor protein activity. In addition, we validated that SHCBP1 mRNA expression was over-expressed in gastrointestinal cancers. CONCLUSIONS: This study was the first to systematically determine the prognostic value of SHCBP1, providing a forward-looking perspective on immunotherapy and cellular processes in pan-cancer.

Subjects

MeSH terms (MEDLINE)

NeoplasmsHumansPrognosisBiomarkersImmunotherapyCell Cycle ProteinsMicrosatellite InstabilityRNA, MessengerTumor MicroenvironmentShc Signaling Adaptor Proteins

Author keywords

SHCBP1biomarkerimmune microenvironmentpan-cancerprognosis

Substances

BiomarkersCell Cycle ProteinsRNA, MessengerSHCBP1 protein, humanShc Signaling Adaptor Proteins

Authors and institutions

  • Department of General Surgery, Fuyang Hospital of Anhui Medical University, Fuyang, Anhui, China.
  • Hepatopancreatobiliary Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
  • Department of Pathology, Anhui Medical University, Hefei, Anhui, China.
  • Department of Oncology, Fuyang Hospital of Anhui Medical University, Fuyang, Anhui, China.
  • School of Basic Medicine, Hebei Medical University, Shijiazhuang, Hebei, China.
  • The Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu, China.

Cite

APA

Jiang, F., Shi, Y., Wang, Y., Ge, C., Zhu, J., Fang, H., Zhang, Y., Zhang, Y., Jian, H., Lei, T., Lan, S., Cao, L., Yu, H., & Fang, D. (2023). Characterization of SHCBP1 to prognosis and immunological landscape in pan-cancer: novel insights to biomarker and therapeutic targets. Aging. https://doi.org/10.18632/aging.204591

Vancouver

Jiang F, Shi Y, Wang Y, Ge C, Zhu J, Fang H, et al. Characterization of SHCBP1 to prognosis and immunological landscape in pan-cancer: novel insights to biomarker and therapeutic targets. Aging. 2023. doi:10.18632/aging.204591

BibTeX
@article{Jiang2023,
  author = {Jiang, Fei and Shi, Yanlong and Wang, Yue and Ge, Chang and Zhu, Jun and Fang, Hanlu and Zhang, Yu and Zhang, Yixiao and Jian, Haokun and Lei, Tong and Lan, Sheng and Cao, Liyu and Yu, Hongzhu and Fang, Debao},
  title = {Characterization of SHCBP1 to prognosis and immunological landscape in pan-cancer: novel insights to biomarker and therapeutic targets},
  journal = {Aging},
  year = {2023},
  doi = {10.18632/aging.204591}
}
Start for free →